| Literature DB >> 35505380 |
Juan Liu1, Li-Qun He1, Wei Zhu1, Gang-Feng Duan1, Yong Fang1, Ying Feng1, Li-Qun Tian1, Qiong-Li Zheng2.
Abstract
BACKGROUND: Diabetes and impaired glucose regulation are very common in patients with coronary artery disease (CAD). In this study, we aim to investigate the prevalence of abnormal glucose regulation in men and women in Chinese CAD patients.Entities:
Keywords: Coronary artery disease; Diabetes; IGT; OGTT; Women
Mesh:
Substances:
Year: 2022 PMID: 35505380 PMCID: PMC9066952 DOI: 10.1186/s13019-022-01848-0
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.522
Classification of glucometabolic state
| Glucometabolic state | Glucose concentration, mmol/L (mg/dL) | |
|---|---|---|
| OGTT | FPG | |
| Normal glucose regulation | ||
| Fasting | < 6.1 (110) | < 6.1 (110) |
| 2 h post-load | < 7.8 (140) | – |
| IGT | ||
| Fasting | < 7.0 (126) | < 7.0 (126) |
| 2 h post-load | 7.8–11.0 (140–199) | – |
| IFG | ||
| Fasting | 6.1–7.0 (110–126) | 6.1–7.0 (110–126) |
| 2 h post-load | < 7.8 (140) | – |
| New DM (NDM) | ||
| Fasting | ≥ 7.0 (126) | ≥ 7.0 (126) |
| 2 h post-load | ≥ 11.1 (126) | – |
Fig. 1Flow diagram of the patient distribution
Patient baseline demographics
| Characteristics | Male (n = 1340) | Female (n = 572) | ||||||
|---|---|---|---|---|---|---|---|---|
| DM (n = 636) | NDM (n = 83) | IGR (n = 283) | Normal (n = 338) | DM (n = 317) | NDM (n = 41) | IGR (n = 105) | Normal (n = 109) | |
| Age (years) | 62 (54–70) | 58 (54–67) | 59 (52–69) | 60 (53–69) | 68 (61–74) | 64 (59–70) | 63 (55–68) | 63 (57–68) |
| Weight (kg) | 72 (65–78) | 71 (64–80) | 72 (66–78) | 70 (63–75) | 63 (55–70) | 65 (55–80) | 61 (56–69) | 60 (54–67) |
| Systolic BP (mmHg) | 130 (120–145) | 130 (120–143) | 130 (120–140) | 130 (120–140) | 140 (120–158) | 142 (130–160) | 130 (120–142) | 130 (120–144) |
| Diastolic BP (mmHg) | 80 (70–89) | 85 (74–90) | 80 (70–90) | 80 (73–88) | 80 (70–90) | 85 (76–90) | 80 (72–90) | 80 (73–83) |
| Heart rate (beats/min) | 72 (65–80) | 73 (65–78) | 70 (63–78) | 70 (62–77) | 72 (65–79) | 71 (67–78) | 70 (65–78) | 70 (62–77) |
Data were median (lower–upper quartiles)
DM, diabetes mellitus; NDM, new diabetes mellitus; IGR, impaired glucose regulation
CAD diagnosis and baseline medical history
| Type | Male | Female | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| DM (n = 636) | NDM (n = 83) | IGR (n = 283) | Normal (n = 338) | Total (n = 1340) | DM (n = 317) | NDM (n = 41) | IGR (n = 105) | Normal (n = 109) | Total (n = 572) | |
| CAD | ||||||||||
| SAP | 20 (3) | 4 (5) | 9 (3) | 25 (7) | 58 (4) | 24 (8) | 2 (5) | 17 (16) | 15 (14) | 58 (10) |
| Previous MI | 128(20) | 8 (10) | 43 (15) | 38 (11) | 217 (16) | 41 (13) | 6 (15) | 8 (8) | 6 (6) | 61 (11) |
| ACS | ||||||||||
| UAP | 319 (50) | 39 (47) | 151(53) | 215 (64) | 724 (54) | 181(57) | 24 (59) | 68 (65) | 81 (74) | 354 (62) |
| STEMI | 120 (19) | 29 (35) | 68 (24) | 55 (16) | 272 (20) | 49 (16) | 7 (17) | 12 (11) | 7 (6) | 75 (13) |
| NSTEMI | 49 (8) | 3 (4) | 12 (4) | 5 (2) | 69 (5) | 22 (7) | 2 (5) | 0 (0) | 0 (0) | 24 (4) |
| Medical history | ||||||||||
| Hypertension | 461 (73) | 53 (64) | 172(61) | 203 (60) | 889 (66) | 258 (81) | 31 (76) | 74 (71) | 79 (73) | 442 (77) |
| Stroke | 12 (2) | 0 (0) | 5 (2) | 1 (< 1) | 18 (1) | 7 (2) | 1 (2) | 0 (0) | 3 (3) | 11 (2) |
| Heart failure | 117 (18) | 13 (16) | 43 (15) | 34 (10) | 207 (15) | 72 (23) | 8 (20) | 13 (12) | 16 (15) | 109 (19) |
| Smoking | ||||||||||
| Current | 367 (58) | 54 (65) | 182 (64) | 195 (58) | 798 (60) | 19 (6) | 5 (12) | 4 (4) | 3 (3) | 31 (5) |
| Former | 43 (7) | 3 (4) | 14 (5) | 24 (7) | 84 (6) | 2 (1) | 0 (0) | 1 (1) | 0 (0) | 3 (1) |
| Never | 226 (35) | 26 (31) | 87 (31) | 119 (35) | 458 (34) | 296 (93) | 36 (88) | 100 (95) | 106 (97) | 538 (94) |
Data are number of patients (%)
SAP, stable angina pectoris; UAP, unstable angina pectoris; DM, diabetes mellitus; NDM, new diabetes mellitus; IGR, impaired glucose regulation
Pharmacological treatment given to patients
| Type | Male | Female | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| DM (n = 636) | NDM (n = 83) | IGR (n = 283) | Normal (n = 338) | Total (n = 1340) | DM (n = 317) | NDM (n = 41) | IGR (n = 105) | Normal (n = 109) | Total (n = 572) | |
| β-Blocker | 520 (82) | 61 (74) | 233 (82) | 276 (82) | 1090 (81) | 225 (71) | 29 (71) | 85 (81) | 85 (78) | 424 (74) |
| ACEI/ARB | 553 (87) | 70 (84) | 254 (90) | 290 (86) | 1167 (87) | 251 (79) | 32 (78) | 88 (84) | 86 (79) | 457 (80) |
| Diuretics | 153 (24) | 18 (22) | 55 (19) | 40 (12) | 266 (20) | 109 (34) | 6 (15) | 12 (11) | 17 (16) | 144 (25) |
| Statins | 563 (89) | 75 (90) | 252 (89) | 312 (92) | 1202 (90) | 267 (84) | 38 (93) | 92 (88) | 90 (87) | 493 (86) |
| CCB | 345 (54) | 45 (54) | 154 (54) | 177 (52) | 721 (54) | 190 (60) | 26 (63) | 77 (73) | 54 (50) | 347 (61) |
| Nitrates | 422 (66) | 63 (76) | 207 (73) | 247 (73) | 439 (70) | 238 (75) | 31 (76) | 64 (61) | 74 (68) | 407 (71) |
| Aspirin | 613 (96) | 82 (99) | 276 (98) | 334 (99) | 1305 (97) | 282 (89) | 41 (100) | 96 (91) | 107 (98) | 526 (92) |
| Clopidogrel | 538 (85) | 80 (96) | 254 (90) | 317 (94) | 1189 (89) | 254 (80) | 35 (85) | 85 (81) | 89 (82) | 463 (81) |
| Oral agents | 364 (67) | 170 (53) | ||||||||
| Insulin | 147 (23) | 73 (23) | ||||||||
| Combined | 77 (12) | 40 (13) | ||||||||
| No drugs/ Diet | 48 (8) | 34 (11) | ||||||||
Data were number of patients (%)
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DM, diabetes mellitus; NDM, new diabetes mellitus; IGR, impaired glucose regulation
Echocardiography findings
| Male(n = 1340) | Female(n = 572) | |||||||
|---|---|---|---|---|---|---|---|---|
| DM (n = 636) | NDM (n = 83) | IGR (n = 283) | Normal (n = 338) | DM (n = 317) | NDM (n = 41) | IGR (n = 105) | Normal (n = 109) | |
| L.A | 3.9 (3.6,4.3) | 3.7 (3.3,4.1) | 3.7 (3.5,4.1) | 3.7 (3.4,4.0) | 3.8 (3.5,4.2) | 3.8 (3.4,4.0) | 3.6 (3.4,3.9) | 3.6 (3.3,4.1) |
| L.V | 5.0 (4.7,5.5) | 5.0 (4.7,5.4) | 4.9 (4.6,5.3) | 4.8 (4.5,5.2) | 4.8 (4.5,5.3) | 4.7 (4.5,5.1) | 4.6 (4.3,4.8) | 4.6 (4.4,5.0) |
| R.A | 3.7 (3.5,4.0) | 3.8 (3.5,4.0) | 3.7 (3.5,4.0) | 3.7 (3.4,3.9) | 3.6 (3.3,3.9) | 3.4 (3.2,3.8) | 3.4 (3.2,3.6) | 3.5 (3.3,3.7) |
| R.V | 3.6 (3.3,3.8) | 3.6 (3.3,3.9) | 3.6 (3.3,3.8) | 3.6 (3.3,3.8) | 3.4 (3.2,3.7) | 3.3 (3.0,3.5) | 3.3 (3.1,3.6) | 3.4 (3.2,3.6) |
| Ao | 3.4 (3.2,3.7) | 3.5 (3.2,3.6) | 3.4 (3.1,3.7) | 3.4 (3.2,3.6) | 3.3 (3.1,3.6) | 3.3 (3.1,3.5) | 3.4 (3.0,3.6) | 3.3 (3.1,3.6) |
| EF | 60 | 60 | 61 | 64 | 62 | 64 | 66 | 66 |
| (50,67) | (47,66) | (55,68) | (56,70) | (50,69) | (59,70) | (62,70) | (60,70) | |
| IVS | 1 | 1 | 1 | 1 | 1 | 1 | 0.9 | 0.9 |
Data are median (lower–upper quartiles)
LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle; Ao, aortic root; IVS, interventricular septum; EF, ejection fraction; DM. diabetes mellitus; NDM, new diabetes mellitus; IGR, impaired glucose regulation
Lipid profile and blood glucose analysis of patients
| Male (n = 1340) | Female (n = 572) | |||||||
|---|---|---|---|---|---|---|---|---|
| DM (n = 636) | NDM (n = 83) | IGR (n = 283) | Normal (n = 338) | DM (n = 317) | NDM (n = 41) | IGR (n = 105) | Normal (n = 109) | |
| Lipid profile | ||||||||
| TC | 3.81 (3.28,4.55) | 3.92 (3.50,5.08) | 4.07 (3.41,4.71) | 3.99 (3.38,4.61) | 4.05 (3.47,4.76) | 4.31 (3.67,5.02) | 4.17 (3.58,4.83) | 4.46 (3.70,4.96) |
| HDL-C | 1.04 (0.88,1.24) | 1.02 (0.90,1.24) | 1.10 (0.94,1.28) | 1.12 (0.97,1.30) | 1.16 (0.95,1.39) | 1.27 (1.08,1.54) | 1.23 (1.07,1.45) | 1.34 (1.14,1.54) |
| LDL-C | 1.96 (1.54,2.51) | 2.22 (1.77,3.05) | 2.20 (1.64,2.66) | 2.13 (1.62,2.63) | 2.11 (1.61,2.75) | 2.41 (1.61,2.82) | 2.03 (1.60,2.52) | 2.31 (1.71,2.71) |
| TG | 1.52 (1.10,2.20) | 1.48 (1.12,2.31) | 1.39 (1.04,2.04) | 1.35 (0.98,1.93) | 1.44 (1.06,2.02) | 1.48 (1.15,2.04) | 1.54 (1.10,2.01) | 1.39 (1.01,1.84) |
| Blood glucose | ||||||||
| RBG | 10.4 (7.6,12.7) | 9.7 (8.1,13.1) | 6.8 (5.4,7.6) | 6.3 (5.3,7.3) | 13.2 (9.6,15.6) | 10.1 (8.0,11.5) | 7.4 (6.2,10.2) | 6.7 (6.4,7.3) |
| FBG | 6.7 (5.3,7.9) | 5.7 (4.9,6.5) | 4.9 (4.4,5.4) | 4.7 (4.0,5.0) | 7 (6.1,9.6) | 5.6 (5.6,6.6) | 4.9 (4.8,5.0) | 4.8 (4.5,5.1) |
| OGTT- 0Hr | 5.7 (4.8,6.6) | 5.1 (4.8,5.6) | 4.4 (4.0,5.2) | 4.4 (4.1,4.8) | 6.4 (5.1,9.1) | 5.4 (4.9,5.9) | 4.6 (4.4,4.9) | 4.4 (4.1,4.5) |
| OGTT—2Hr | 14.2 (12.0,15.3) | 13.2 (12.5,15.0) | 9.1 (8.5,9.7) | 6.0 (5.3,7.0) | 13.6 (12.1,15.8) | 12.3 (11.6,13.6) | 8.3 (7.8,8.6) | 6.1 (5.6,6.7) |
| HbA1C | 6.6 (6.2,7.6) | 6 (5.9,6.4) | 5.7 (5.3,6.4) | 5.6 (5.4,5.8) | 7.2 (6.6,8.5) | 6.1 (6.1,6.2) | 6.1 (5.9,6.2) | 5.6 (5.3,5.9) |
Data were median (lower–upper quartiles)
TC, total cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, triglyceride; RBG, random blood glucose; FBG, fasting blood glucose; DM, diabetes mellitus; NDM, new diabetes mellitus; IGR, impaired glucose regulation
Glucose regulation in men and women in the study population
| Population | Glucometabolic status | Total | |||||
|---|---|---|---|---|---|---|---|
| DM | NDM | IGT | IFG | Normal | |||
| Women | 317 | 41 | 97 | 8 | 109 | 572 | 0.003 |
| Men | 636 | 83 | 274 | 9 | 338 | 1340 | |
| Total | 953 | 124 | 371 | 17 | 447 | 1912 | |
DM, diabetes mellitus; NDM, new diabetes mellitus; IGT, impaired glucose tolerance; IFG, impaired fasting glycemia
Pearson Chi-Square Test is used and a value of p < 0.05 is considered significant